Go Pro

DaVita (DVA) Stock Price, News & Analysis

DaVita logo
$234.79 -0.12 (-0.05%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$234.10 -0.69 (-0.30%)
As of 07/2/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About DaVita Stock (NYSE:DVA)

Advanced

Key Stats

Today's Range
$230.58
$236.51
50-Day Range
$150.14
$234.79
52-Week Range
$101.00
$236.51
Volume
830,603 shs
Average Volume
802,619 shs
Market Capitalization
$15.07 billion
P/E Ratio
21.78
Dividend Yield
N/A
Price Target
$199.17
Consensus Rating
Hold

Company Overview

DaVita Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

DVA MarketRank™: 

DaVita scored higher than 82% of companies evaluated by MarketBeat, and ranked 96th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DaVita has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 1 strong buy rating, 2 buy ratings, 4 hold ratings, and 1 sell rating.

  • Downside Risk

    DaVita has a consensus price target of $199.17, representing about 15.2% downside from its current price of $234.79.

  • Amount of Analyst Coverage

    DaVita has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about DaVita's stock forecast and price target.
  • Earnings Growth

    Earnings for DaVita are expected to grow by 21.90% in the coming year, from $15.07 to $18.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DaVita is 21.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.58.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DaVita is 21.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.02.

  • Price to Earnings Growth Ratio

    DaVita has a PEG Ratio of 0.77. PEG Ratios below 1 indicate that a company could be undervalued.

  • Read more about DaVita's valuation and earnings.
  • Percentage of Shares Shorted

    7.32% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 5.97.
  • Change versus previous month

    Short interest in DaVita has recently decreased by 4.68%, indicating that investor sentiment is improving.
  • Dividend Yield

    DaVita does not currently pay a dividend.

  • Dividend Growth

    DaVita does not have a long track record of dividend growth.

  • News Sentiment

    DaVita has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for DaVita this week, compared to 5 articles on an average week.
  • Search Interest

    Only 12 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DaVita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,097,981.00 in company stock.

  • Percentage Held by Insiders

    1.50% of the stock of DaVita is held by insiders.

  • Percentage Held by Institutions

    90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DaVita's insider trading history.
Receive DVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DVA Stock News Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Is DaVita Inc. (DVA) A Good Stock To Buy Now?
See More Headlines

DVA Stock Analysis - Frequently Asked Questions

DaVita's stock was trading at $113.74 on January 1st, 2026. Since then, DVA stock has increased by 106.4% and is now trading at $234.79.

DaVita Inc. (NYSE:DVA) announced its earnings results on Tuesday, May, 5th. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.33 by $0.54. The business's revenue for the quarter was up 6.0% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others.

DaVita's top institutional investors include CX Institutional. Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty and Barbara J Desoer.
View institutional ownership trends
.

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/05/2026
Today
7/05/2026
Next Earnings (Estimated)
8/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Health Care Services
Current Symbol
NYSE:DVA
CIK
927066
Employees
78,000
Year Founded
1994

Price Target and Rating

High Price Target
$235.00
Low Price Target
$140.00
Potential Upside/Downside
-15.2%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$10.78
Trailing P/E Ratio
21.78
Forward P/E Ratio
15.58
P/E Growth
0.77
Net Income
$746.80 million
Net Margins
5.65%
Pretax Margin
10.13%
Return on Equity
-270.37%
Return on Assets
4.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.42
Quick Ratio
1.37

Sales & Book Value

Annual Sales
$13.64 billion
Price / Sales
1.10
Cash Flow
$21.70 per share
Price / Cash Flow
10.82
Book Value
($5.29) per share
Price / Book
-44.38

Miscellaneous

Outstanding Shares
64,200,000
Free Float
63,237,000
Market Cap
$15.07 billion
Optionable
Optionable
Beta
0.88

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSE:DVA) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners